A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
A phase 3 trial testing HLX11 in HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, active and no longer recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer is a phase 3 interventional study registered as NCT05346224, led by Shanghai Henlius Biotech, and active but no longer recruiting when checked on 2026-09-11. Official title: A Multicenter, Randomised, Double-Blind, Parallel-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Pertuzumab Biosimilar HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer. Planned enrolment is 900 participants (estimated). The study started in 2022-04-25 and primary completion is expected in 2024-05-15. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Shares Shanghai Henlius Biotech and the tag ctgov-ingest.
- TrialA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shares Shanghai Henlius Biotech and the tag ctgov-ingest.
- TrialA Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialClinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialA Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag ctgov-ingest.
- TrialIBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Shares HER2-positive breast cancer and the tag ctgov-ingest.